Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Mariel Metcalfe
  • July 14, 2017
  • Articles

Living with Lupus: Breaking the Silence

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Lupus is an almost invisible disease, yet can have considerable impact on patients’ quality of life, but there is much that pharma can do to help.

read more »

  • Posted by Mariel Metcalfe
  • February 8, 2017
  • News

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

SLE is a progressive and debilitating disease which affects 5 million people worldwide. Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US, France and Germany. The report consists of 30-minute online interviews with 262 SLE patients (including those with lupus nephritis); fifteen follow-up qualitative interviews were also conducted. All patients were required to be on an immunosuppressant or biologic therapy; the final sample includes 15-20% on biologics.

read more »

  • Posted by Allison Fleetwood
  • June 30, 2014
  • News

Lupus study reveals Benlysta favoured as future biologic of choice

Lupus study reveals Benlysta favoured as future biologic of choice

With Benlysta’s approval and further drugs in the pipeline, the market for SLE is expected to grow substantially over the next 10 years, making this fast-changing disease area a key market to watch.

With Benlysta’s approval and further drugs in the pipeline, the market for SLE is expected to grow substantially over the next 10 years, making this fast-changing disease area a key market to watch. Wave one of Therapy Watch Lupus (SLE) provided us with a snapshot of the SLE market, identifying the current market trends which will most likely impact future brand strategy.
The study revealed that, despite its focus on SLE, Benlysta’s uptake has been more gradual than many predicted since its approval and it currently holds a similar proportion of the market as Rituximab/MabThera, which is prescribed off-label.

read more »

  • Posted by Julie Denny
  • March 25, 2014
  • News

Therapy Watch launches Lupus, a new patient tracking study

Recently, we’ve seen a change in the treatment landscape for lupus with biologics increasingly being used to control the disease. In light of this, and because of client demand, we are expanding our portfolio of autoimmune products to now include Therapy Watch Lupus.

To keep in step with the market dynamics as they happen, Therapy Watch Lupus will be a quarterly study amongst 280 rheumatologists across France, Germany, Italy, Brazil, Canada and the US, submitting information on 2,000+ patients each wave.

read more »